Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.

@article{Walsh1998EffectsOR,
  title={Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.},
  author={Brian W. Walsh and Lewis H. Kuller and Robert A. Wild and Sofia Paul and Mildred V. Farmer and Jeffry B. Lawrence and A S Shah and Pamela W. Anderson},
  journal={JAMA},
  year={1998},
  volume={279 18},
  pages={
          1445-51
        }
}
CONTEXT Raloxifene is a selective estrogen receptor modulator that has estrogen-agonistic effects on bone and estrogen-antagonistic effects on breast and uterus. OBJECTIVE To identify the effects of raloxifene on markers of cardiovascular risk in postmenopausal women, and to compare them with those induced by hormone replacement therapy (HRT). DESIGN Double-blind, randomized, parallel trial. SETTING Eight sites in the United States. PARTICIPANTS 390 healthy postmenopausal women… 

Figures and Tables from this paper

Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women.

The results of this study show that raloxifene at a dose of 60 mg/d reduces serum concentrations of low-density lipoprotein cholesterol and total cholesterol in healthy older women and may have a favorable effect on the incidence of cardiovascular disease in older women.

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years

The main objectives of these analyses are to compare the effect of 5 years of treatment with raloxifene (60 mg/day) with placebo in terms of the likelihood of developing osteoporosis and to evaluate the effect on the endometrium and incidence of vaginal bleeding.

Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study.

It is suggested that in healthy postmenopausal women, raloxifene and estrogen monotherapy have similar beneficial effects on low density lipoprotein cholesterol and fibrinogen levels.

A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.

Raloxifene and CEE have beneficial effects on bone density and bone turnover, although effects of CEE are more marked.

Effects of raloxifene therapy on the anticoagulant system in postmenopausal women

The results of this prospective study show for the first time that raloxifene use is associated with a significant reduction in plasma antithrombin activity, which may contribute to a procoagulant state and partly explain the increased risk of venous thromboembolism in ral oxifene users.

Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women.

17-beta Estradiol plus norethindrone produced favorable changes in most cardiovascular risk markers evaluated and has a profile distinct from that of unopposed 17-beta estradiol.

Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women.

Droloxifene has estrogen agonistic properties regarding low densitylipoprotein and lipoprotein(a) metabolism, certain coagulation factors, and endothelium-dependent vasodilation but, unlike estrogen, has no effect on high density lipop protein/triglyceride metabolism and the fibrinolytic cascade.

Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study

Continuous combined HRT was associated with decreases in total cholesterol and LDL cholesterol about twice as large as with raloxifene, but also with a decrease in HDL cholesterol, which may have important implications for the reduction of cardiovascular disease.

Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women.

The decrease of PRL values induced by long-term raloxifene administration in postmenopausal women could be explained by a direct antiestrogenic effect of ralOxifene on lactotrope cells or by the recently suggested increase of opiatergic tone on the hypothalamic-pituitary region.
...

References

SHOWING 1-10 OF 43 REFERENCES

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.

Daily therapy with raloxifene increases bone mineral density, lowers serum concentrations of total and low-density lipoprotein cholesterol, and does not stimulate the endometrium.

A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women

Study results indicate that raloxifene may provide beneficial effects to bone and serum lipids in humans without uterine stimulatory effects.

The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women.

It is concluded that tamoxifen significantly reduces the levels of atherogenic lipids and fibrinogen in normal postmenopausal women, suggesting that the anti-estrogens may substantially reduce the risk of cardiovascular disease, which remains the most common cause of death among post menopausal women.

Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits.

The findings indicate that raloxifene hydrochloride has a potentially important antiatherogenic effect, analogous to that observed with estrogen in this model.

Effect of tamoxifen on measurements of hemostasis in healthy women.

Preliminary findings seem to justify continuation of the double-blind study in healthy women, but only direct comparison of thromboembolic complications in the 2 treatment groups will establish whether tamoxifen carries a risk ofThrombosis.

Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women.

Tamoxifen lowers plasma Lp(a) levels in healthy postmenopausal women, the suppressive effects of tamoxIFen and estrogen on circulating Lp (a) concentration diverge after the first month of therapy, and circulating levels of Lp.(a) and IGF-I are strongly correlated with each other, an indication that they may share regulatory influences.

Coagulation activation following estrogen administration to postmenopausal women.

Data indicate that low doses of oral estrogens frequently increase the amount of thrombin generated in vivo, which may help to explain the increased thrombotic risk that has been observed with higher doses of this medication.

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.

In postmenopausal women, treatment with tamoxifen is associated with preservation of the bone mineral density of the lumbar spine, and whether this favorable effect on bone mineraldensity is accompanied by a decrease in the risk of fractures remains to be determined.

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

Raloxifene has promise as an agent with beneficial bone and cardiovascular effects in the absence of significant uterine effects, and ethynyl estradiol diverged dramatically from estrogen in its lack of significant estrogenic effects on uterine tissue.